All News

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

Your daily dose of the clinical news you may have missed.

Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.

Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.

July 4th invites celebration, typically with alcohol. Try our quiz based on a review of the holiday drinking patterns of US adults. Are answers to these 10 questions what you expect?

Your daily dose of the clinical news you may have missed.

The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.